REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

Sorting 5 by

Memorial Sloan Kettering Cancer Center
New York, NY
Fully Open
  • Not currently accepting
  • Show Principal Investigator
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.